Tonix Pharmaceuticals Holding (TNXP) shares rose sharply on Monday. The stock could remain in focus over the next month as the company is scheduled to release top-line results for its lead product candidate. Positive results could provide a significant boost to TNXP shares, which have been struggling ever since the company’s product candidate episodic tension type headache failed in a proof-of-concept study.